Literature DB >> 22569973

Esophagocardioplasty as surgical treatment in relapsed non advanced megaesophagus.

José Luis Braga de Aquino1, Marcelo Manzano Said, Vânia Aparecida Leandro-Merhi, João Paulo Zenun Ramos, Liliane Ichinoche, Daniel Machado Guimarães.   

Abstract

BACKGROUND: It has always been very controversial to choose an ideal operation for patients with no advanced recurrent megaesophagus after previous treatment. The various existing techniques and the different degrees of disease are the major factors to this difficulty. AIM: To evaluate the early and late results of the Serra-Doria esophagocardioplasty in patients who had recurrence of symptoms in non-advanced megaesophagus after having been submitted to cardiomyotomy.
METHODS: Were studied 32 patients. The age ranged from 32 to 63 years. Nineteen had mild and 13 moderate dysphagia, and 14 had some degree of regurgitation. These subjects underwent the Serra-Doria esophagocardioplasty and were evaluated the local and systemic complications occurred postoperatively.
RESULTS: After the procedure could be followed 27 patients, 22 began to show normal swallowing, five mild dysphagia and three remained with some regurgitation. No patient died. Three had early pneumonia and in one occurred anastomotic leak.
CONCLUSIONS: The Serra-Doria esophagocardioplasty is adequate procedure for the surgical treatment of relapsed non advanced megaesophagus.

Entities:  

Mesh:

Year:  2012        PMID: 22569973     DOI: 10.1590/s0102-67202012000100005

Source DB:  PubMed          Journal:  Arq Bras Cir Dig        ISSN: 0102-6720


  1 in total

1.  Lingual salivary gland hypertrophy and decreased acinar density in chagasic patients without megaesophagus.

Authors:  Bárbara Bellocchio Bertoldo; Renata Margarida Etchebehere; Taíssa Cássia de Souza Furtado; Juliana Barbosa de Faria; Camilla Beatriz Silva; Márcia Fernandes de Araújo; Denise Bertulucci Rocha Rodrigues; Sanivia Aparecida de Lima Pereira
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2019-12-20       Impact factor: 1.846

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.